Overexpression of synuclein-γ predicts lack of benefit from radiotherapy for breast cancer patients.

ABSTRACT:

Background

Although radiotherapy following mastectomy was demonstrated to reduce the recurring risk and improve the prognosis of patients with breast cancer, it is also notorious for comprehensive side effects, hence only a selected group of patients can benefit. Therefore, the screening of molecular markers capable of predicting the efficacy of radiotherapy is essential.

Methods

We have established a cohort of 454 breast cancer cases and selected 238 patients with indications for postoperative radiotherapy. Synuclein-γ (SNCG) protein levels were assessed by immunohistochemistry, and SNCG status was retrospectively correlated with clinical features and survival in patients treated or not treated with radiotherapy. Gene Set Enrichment Analysis (GSEA) and survival analysis for

SUBMITTER: Min L 

PROVIDER: S-EPMC5011985 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature